Edwards Lifesciences Corporation (NYSE:EW) Given Average Rating of “Moderate Buy” by Analysts

Shares of Edwards Lifesciences Corporation (NYSE:EW) have received an average recommendation of “Moderate Buy” from the twenty-seven research firms that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating, fourteen have given a buy rating and three have given a strong buy rating to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $93.9545.

Several brokerages have issued reports on EW. Citigroup reiterated a “buy” rating and issued a $101.00 price target (up previously from $96.00) on shares of Edwards Lifesciences in a report on Thursday, December 11th. Truist Financial set a $92.00 target price on Edwards Lifesciences and gave the stock a “hold” rating in a report on Friday, December 5th. Royal Bank Of Canada lifted their price target on shares of Edwards Lifesciences from $95.00 to $100.00 and gave the company an “outperform” rating in a research report on Friday, December 5th. Canaccord Genuity Group set a $87.00 price objective on shares of Edwards Lifesciences and gave the stock a “hold” rating in a report on Wednesday, December 17th. Finally, Raymond James Financial raised shares of Edwards Lifesciences from a “market perform” rating to an “outperform” rating and set a $96.00 price objective on the stock in a research note on Monday, November 3rd.

Edwards Lifesciences Stock Up 0.1%

Shares of NYSE EW opened at $86.94 on Thursday. The company has a quick ratio of 3.29, a current ratio of 4.00 and a debt-to-equity ratio of 0.06. The firm has a market cap of $50.45 billion, a PE ratio of 37.47, a P/E/G ratio of 3.90 and a beta of 0.97. The company’s fifty day simple moving average is $84.08 and its 200 day simple moving average is $79.71. Edwards Lifesciences has a 12-month low of $65.94 and a 12-month high of $87.89.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.59 by $0.08. The firm had revenue of $1.55 billion during the quarter, compared to the consensus estimate of $1.49 billion. Edwards Lifesciences had a net margin of 23.25% and a return on equity of 14.70%. The business’s revenue was up 14.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.67 earnings per share. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. As a group, sell-side analysts forecast that Edwards Lifesciences will post 2.45 earnings per share for the current fiscal year.

Insider Activity at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 11,386 shares of the firm’s stock in a transaction that occurred on Friday, December 12th. The stock was sold at an average price of $83.76, for a total value of $953,691.36. Following the transaction, the vice president owned 38,970 shares in the company, valued at $3,264,127.20. This trade represents a 22.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Scott B. Ullem sold 13,000 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, November 10th. The shares were sold at an average price of $83.08, for a total value of $1,080,040.00. Following the transaction, the chief financial officer directly owned 39,898 shares in the company, valued at approximately $3,314,725.84. The trade was a 24.58% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 45,465 shares of company stock valued at $3,804,610. 0.34% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Edwards Lifesciences

Several large investors have recently bought and sold shares of EW. JPL Wealth Management LLC purchased a new stake in shares of Edwards Lifesciences in the third quarter valued at about $25,000. Quantbot Technologies LP bought a new stake in Edwards Lifesciences in the 1st quarter worth about $26,000. Rosenberg Matthew Hamilton purchased a new stake in Edwards Lifesciences in the 2nd quarter valued at about $28,000. True Wealth Design LLC increased its stake in Edwards Lifesciences by 251.5% in the 3rd quarter. True Wealth Design LLC now owns 362 shares of the medical research company’s stock valued at $28,000 after buying an additional 259 shares during the last quarter. Finally, NewSquare Capital LLC lifted its position in shares of Edwards Lifesciences by 57.8% during the 2nd quarter. NewSquare Capital LLC now owns 366 shares of the medical research company’s stock worth $29,000 after buying an additional 134 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.